The estimated Net Worth of Todd Alfred Carter is at least $776 Tisíc dollars as of 20 February 2024. Todd Carter owns over 3,967 units of Voyager Therapeutics Inc stock worth over $550,298 and over the last 2 years Todd sold VYGR stock worth over $225,932.
Todd has made over 10 trades of the Voyager Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Todd sold 3,967 units of VYGR stock worth $29,753 on 20 February 2024.
The largest trade Todd's ever made was selling 10,500 units of Voyager Therapeutics Inc stock on 15 September 2023 worth over $85,680. On average, Todd trades about 2,621 units every 34 days since 2022. As of 20 February 2024 Todd still owns at least 87,627 units of Voyager Therapeutics Inc stock.
You can see the complete history of Todd Carter stock trades at the bottom of the page.
Todd's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 a Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include: